Program Suspension 133 mg Suspension is a Health Canada–registered veterinary drug (DIN 02057832) held by Elanco Canada Limited, containing Lufenuron. Health Canada lists its status as Cancelled Post Market (status date 30 Jul 2026). Nexara Health has matched 4 registrations of Lufenuron across 1 other regulated market.
Health Canada registration
| DIN | 02057832 |
|---|---|
| Brand name | Program Suspension |
| Active ingredient | Lufenuron |
| Strength | 133 mg |
| Dosage form | Suspension |
| Route | Oral |
| Company | Elanco Canada Limited |
| Status | Cancelled Post Market — 30 Jul 2026 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Status and company history
Changes Health Canada has recorded for this DIN, as observed by Nexara Health's weekly DPD comparison.
| Date | Field | From | To |
|---|---|---|---|
| 2026-09-03 | Status | Dormant | Cancelled Post Market |
| 2026-09-03 | Status | Dormant | Cancelled Post Market |
Lufenuron registered in other markets
4 registrations of the same molecule in 1 national registry outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Lufenuron | Lonza AG | Powder | FDA NDC | ||
| United States | Lufenuron | Hubei Honch Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Lufenuron | Laurus Synthesis Pvt Ltd | Powder | FDA NDC | ||
| United States | Lufenuron | Alivira Animal Health Limited | Powder | FDA NDC |
See every manufacturer of Lufenuron worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Program Suspension (DIN 02057832) marketed in Canada?
No. Health Canada lists DIN 02057832 as Cancelled Post Market as of 30 Jul 2026.
Who holds the Canadian licence for this product?
Elanco Canada Limited is the company of record in the Health Canada Drug Product Database.
Is Lufenuron registered outside Canada?
Yes — Nexara Health has matched 4 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02057832, status date 2026-07-30; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02057832, status date 2026-07-30; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02057832, status date 2026-07-30; national medicine registries: FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.